Browse studies

Find your next paid study

7 recruiting studies matching your filters

DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins

The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibro…

NeurofibromasMPNST

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT07298083

Phase 2

Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor ZEN-3694 With Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors

A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST…

MPNSTNF1Sarcoma

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT05253131

Phase 1

A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-…

Synovial SarcomaMalignant Peripheral Nerve Sheath Tumor (MPNST)Neuroblastoma (NBL)+1 more

Estimated

~$10 – $8,750

USWM CT, LLCNCT05642455

Phase 1

A Phase II Trial to Assess the Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor Patients With Homozygous MTAP Deletion

People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new…

Malignant Peripheral Nerve Sheath TumorsMPNST

Estimated

~$10 – $7,500

Ankit Mangla, MDNCT07549022

Phase 1

Early Phase Study to Evaluate the MEK Inhibitor Selumetinib With the MDM2 Inhibitor APG-115 in Patients With Neurofibromatosis Type 1 and Pre-malignant and Malignant Peripheral Nerve Sheath Tumors

This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and…

Malignant Peripheral Nerve Sheath Tumor (MPNST)Neurofibromatosis 1 (NF1)Atypical Neurofibroma

Estimated

~$10 – $7,500

AeRang KimNCT06735820

Phase 2

A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors

The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPN…

Wilms TumorRhabdoid TumorMalignant Peripheral Nerve Sheath Tumors+4 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05985161

Phase 2

A Phase II Study of ASTX727 in Patients With PRC2 Loss Malignant Peripheral Nerve Sheath Tumor (MPNST)

The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a comb…

Malignant Peripheral Nerve Sheath Tumors (MPNST)

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT04872543